Cardiac amyloidosis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(8 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Cardiac amyloidosis}}
{{Cardiac amyloidosis}}
{{CMG}}; {{AE}} {{AN}}; {{RT}}
{{CMG}}; {{AE}} {{AN}}; {{RT}}{{Sab}}
 
==Overview==
The [[incidence]] rate increased from 18 to 55 per 100,000 person-years from 2000 to 2012. The [[prevalence]] rate increased from 8 to 17 per 100 000 person-years from 2000 to 2012. Cardiac amyloidosis commonly presents in adults more than 40 years old. The [[incidence]] and [[prevalence]] of cardiac amyloidosis have increased among blacks from 2000 to 2012. Over the years, both [[incidence]] and [[prevalence]] of cardiac amyloidosis have increased among men.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
* The [[incidence]] rate increased from 18 to 55 per 100,000 person-years from 2000 to 2012.<ref name="pmid311708022">{{cite journal |vauthors=Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S |title=Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States |journal=Circ Heart Fail |volume=12 |issue=6 |pages=e005407 |date=June 2019 |pmid=31170802 |doi=10.1161/CIRCHEARTFAILURE.118.005407 |url=}}</ref>
* There were 4746 [[Incidence|incident]] cases of cardiac amyloidosis in the US in 2012.<ref name="pmid31170802">{{cite journal |vauthors=Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S |title=Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States |journal=Circ Heart Fail |volume=12 |issue=6 |pages=e005407 |date=June 2019 |pmid=31170802 |doi=10.1161/CIRCHEARTFAILURE.118.005407 |url=}}</ref>
===Prevalence===
* The [[prevalence]] rate increased from 8 to 17 per 100 000 person-years from 2000 to 2012.<ref name="pmid311708023">{{cite journal |vauthors=Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S |title=Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States |journal=Circ Heart Fail |volume=12 |issue=6 |pages=e005407 |date=June 2019 |pmid=31170802 |doi=10.1161/CIRCHEARTFAILURE.118.005407 |url=}}</ref>
* There were 15,737 [[Prevalence|prevalent]] cases of cardiac amyloidosis in 2012.
===Age===
===Age===
* In the United States, it has been estimated that there are 1.3 million gene carries and that there are approximately 150,000 carriers over the age of 60 years.
* In the United States, it has been estimated that there are 1.3 million gene carries and that there are approximately 150,000 carriers over the age of 60 years.
Line 9: Line 22:
*Senile type of cardiac amyloidosis typically presents after 60 years of age, most commonly after 70 years of age.
*Senile type of cardiac amyloidosis typically presents after 60 years of age, most commonly after 70 years of age.
* Various mutations of proteins involved in amyloid deposition may present anytime between 30 to 70 years of age.
* Various mutations of proteins involved in amyloid deposition may present anytime between 30 to 70 years of age.
*The [[incidence]] and [[prevalence]] of cardiac amyloisosis have significantly increased among the elderly after 2006.<ref name="pmid311708025">{{cite journal |vauthors=Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S |title=Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States |journal=Circ Heart Fail |volume=12 |issue=6 |pages=e005407 |date=June 2019 |pmid=31170802 |doi=10.1161/CIRCHEARTFAILURE.118.005407 |url=}}</ref>


===Ethnicity===
===Ethnicity===
* 3-4% of African-Americans carry the most common mutation that causes the substitution of Ile for Val at position <ref name="pmid6278822">{{cite journal |author=Dictor M, Hasserius R |title=Systemic amyloidosis and non-hematologic malignancy in a large autopsy series |journal=[[Acta Pathologica Et Microbiologica Scandinavica. Section a, Pathology]] |volume=89 |issue=6 |pages=411–6 |year=1981 |month=November |pmid=6278822 |doi= |url= |accessdate=2012-02-13}}</ref> and is known to contribute to the incidence of [[Cardiac amyloidosis pathophysiology#Familial amyloidotic cardiomyopathy|familial amyloidotic cardiomyopathy]].<ref name="pmid8698351">{{cite journal |author=Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN |title=Revised transthyretin Ile 122 allele frequency in African-Americans |journal=[[Human Genetics]] |volume=98 |issue=2 |pages=236–8 |year=1996 |month=August |pmid=8698351 |doi= |url=http://link.springer.de/link/service/journals/00439/bibs/6098002/60980236.htm |accessdate=2012-02-13}}</ref>
* 3-4% of African-Americans carry the most common [[mutation]] that causes the substitution of Ile for Val at position 122 and is known to contribute to the [[incidence]] of [[Cardiac amyloidosis pathophysiology#Hereditary Transthyretin (TTR)-Related Form (ATTR)|familial amyloidotic cardiomyopathy]].<ref name="pmid6278822">{{cite journal |author=Dictor M, Hasserius R |title=Systemic amyloidosis and non-hematologic malignancy in a large autopsy series |journal=[[Acta Pathologica Et Microbiologica Scandinavica. Section a, Pathology]] |volume=89 |issue=6 |pages=411–6 |year=1981 |month=November |pmid=6278822 |doi= |url= |accessdate=2012-02-13}}</ref><ref name="pmid8698351">{{cite journal |author=Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN |title=Revised transthyretin Ile 122 allele frequency in African-Americans |journal=[[Human Genetics]] |volume=98 |issue=2 |pages=236–8 |year=1996 |month=August |pmid=8698351 |doi= |url=http://link.springer.de/link/service/journals/00439/bibs/6098002/60980236.htm |accessdate=2012-02-13}}</ref>
* After the age of 60, isolated cardiac amyloidosis is four times more common among blacks than whites in the United States.<ref name="pmid9017939">{{cite journal |author=Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN |title=Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans |journal=[[The New England Journal of Medicine]] |volume=336 |issue=7 |pages=466–73 |year=1997 |month=February |pmid=9017939 |doi=10.1056/NEJM199702133360703 |url=http://dx.doi.org/10.1056/NEJM199702133360703 |accessdate=2012-02-13}}</ref>
* After the age of 60, isolated cardiac amyloidosis is four times more common among blacks than whites in the United States.<ref name="pmid9017939">{{cite journal |author=Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN |title=Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans |journal=[[The New England Journal of Medicine]] |volume=336 |issue=7 |pages=466–73 |year=1997 |month=February |pmid=9017939 |doi=10.1056/NEJM199702133360703 |url=http://dx.doi.org/10.1056/NEJM199702133360703 |accessdate=2012-02-13}}</ref>
*The [[incidence]] and [[prevalence]] of cardiac amyloidosis have increased among blacks from 2000 to 2012.<ref name="pmid311708026">{{cite journal |vauthors=Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S |title=Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States |journal=Circ Heart Fail |volume=12 |issue=6 |pages=e005407 |date=June 2019 |pmid=31170802 |doi=10.1161/CIRCHEARTFAILURE.118.005407 |url=}}</ref>


===Gender===
===Gender===
* There is no difference in the incidence of cardiac amyloidosis between men and women as it affects both genders equally.
 
*Over the years, both [[incidence]] and [[prevalence]] of cardiac amyloidosis have increased among men.<ref name="pmid311708024">{{cite journal |vauthors=Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S |title=Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States |journal=Circ Heart Fail |volume=12 |issue=6 |pages=e005407 |date=June 2019 |pmid=31170802 |doi=10.1161/CIRCHEARTFAILURE.118.005407 |url=}}</ref>


==References==
==References==

Latest revision as of 05:46, 4 November 2019

Cardiac amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiac Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac amyloidosis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac amyloidosis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac amyloidosis epidemiology and demographics

CDC onCardiac amyloidosis epidemiology and demographics

Cardiac amyloidosis epidemiology and demographics in the news

Blogs on Cardiac amyloidosis epidemiology and demographics

Directions to Hospitals Treating Cardiac amyloidosis

Risk calculators and risk factors for Cardiac amyloidosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]Sabawoon Mirwais, M.B.B.S, M.D.[4]

Overview

The incidence rate increased from 18 to 55 per 100,000 person-years from 2000 to 2012. The prevalence rate increased from 8 to 17 per 100 000 person-years from 2000 to 2012. Cardiac amyloidosis commonly presents in adults more than 40 years old. The incidence and prevalence of cardiac amyloidosis have increased among blacks from 2000 to 2012. Over the years, both incidence and prevalence of cardiac amyloidosis have increased among men.

Epidemiology and Demographics

Incidence

  • The incidence rate increased from 18 to 55 per 100,000 person-years from 2000 to 2012.[1]
  • There were 4746 incident cases of cardiac amyloidosis in the US in 2012.[2]

Prevalence

  • The prevalence rate increased from 8 to 17 per 100 000 person-years from 2000 to 2012.[3]
  • There were 15,737 prevalent cases of cardiac amyloidosis in 2012.

Age

  • In the United States, it has been estimated that there are 1.3 million gene carries and that there are approximately 150,000 carriers over the age of 60 years.
  • Cardiac amyloidosis commonly presents in adults more than 40 years old.
  • Senile type of cardiac amyloidosis typically presents after 60 years of age, most commonly after 70 years of age.
  • Various mutations of proteins involved in amyloid deposition may present anytime between 30 to 70 years of age.
  • The incidence and prevalence of cardiac amyloisosis have significantly increased among the elderly after 2006.[4]

Ethnicity

  • 3-4% of African-Americans carry the most common mutation that causes the substitution of Ile for Val at position 122 and is known to contribute to the incidence of familial amyloidotic cardiomyopathy.[5][6]
  • After the age of 60, isolated cardiac amyloidosis is four times more common among blacks than whites in the United States.[7]
  • The incidence and prevalence of cardiac amyloidosis have increased among blacks from 2000 to 2012.[8]

Gender

References

  1. ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
  2. ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
  3. ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
  4. ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
  5. ↑ Dictor M, Hasserius R (1981). "Systemic amyloidosis and non-hematologic malignancy in a large autopsy series". Acta Pathologica Et Microbiologica Scandinavica. Section a, Pathology. 89 (6): 411–6. PMID 6278822. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  6. ↑ Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN (1996). "Revised transthyretin Ile 122 allele frequency in African-Americans". Human Genetics. 98 (2): 236–8. PMID 8698351. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
  7. ↑ Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN (1997). "Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans". The New England Journal of Medicine. 336 (7): 466–73. doi:10.1056/NEJM199702133360703. PMID 9017939. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
  8. ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.
  9. ↑ Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (June 2019). "Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States". Circ Heart Fail. 12 (6): e005407. doi:10.1161/CIRCHEARTFAILURE.118.005407. PMID 31170802.


Template:WikiDoc Sources CME Category::Cardiology

Retrieved from "https://www.wikidoc.org/index.php?title=Cardiac_amyloidosis_epidemiology_and_demographics&oldid=1587839"